focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Risk and return. Target price from Numis is £9.90, but they also quote their estimate of success for phase 3 trial at 70% ( slightly above industry average) . So when you read the science, and see the upside possible, only you can make the call if ithe potential for a 6x gain is worth a 30% chance of an unsuccessful tria.
I’m not a poker specialist, but I’m guessing it’s the equivalent of being dealt 2 queens and having another 1 in the flop!!
Just got this response. He sits on the Health committee so he knows!!
The Synairgen treatment trials are already being fast tracked and formed the template for the governments Accord programme that was set up in April to fast track other treatments. Therefore it is progressing through trials more rapidly than would happen under normal circumstances but clearly speed must be tempered with safety.
What’s clear is there wasn’t enough physical stock to run a big trial, which is why we got dropped. The government should have invested at that point ( as they did with the vaccines), instead we had to rely on the accelerated bookbuild to fund the step up in manufacturing. Given that RM said manufacturing slots were severely restricted by vaccine manufacturing requirements, I suspect this is still limiting us. We literally can’t start the trials until November as we don’t have the quantities of stock available.
Sorry, I think you’re too fixated on Covid. The most interesting part of the Rockefeller lecture was that the Interferon response in the first 4 days determines the outcome in all viral attacks. They’ve basically uncovered an opportunity for SNG to be used well beyond Covid and COPD. Our bodies first reaction to all viruses is Interferon, therefore if you have low levels or auto antibodies against Interferon, SNG should be able to help
Given the SP is heading towards the open offer price, anyone else considering voting against the resolution at the general meeting. The 175 price is supposed to be an incentive to shareholders, but will end up diluting our shares, and in the scheme of things, is the £7 million important to Synairgen. Surely the big prize was the £80m accelerated book build. Interesting to know how the American VC’s will vote as I don’t think US shareholders are eligible ( as the documents were not allowed to be shared to US). New to this, so could be wrong on many of my thoughts here. By the way thanks for all of the research and discussion, it’s great to be a part of this community
Cut off to accept initial allocation is Monday I think, once they know how many have been taken up, excess shares will be allocated. AJB has them on 2 separate lines - guaranteed allocation, and application for excess. Not sure when allocation is confirmed, but shares go live on 4th Nov.
All of this only happens if shareholders vote to accept the additional placement at the general meeting next week, which your broker should have asked for your voting preferences.
The interesting question is if the share price is going down to offer price, should we reject the motion at the general meeting as we get diluted for no benefit
Anyone who has a broker account has an open allocation of shares, and a second line which invites applications for excess shares ( those allocations not taken up by shareholders) this has effectively killed the retail investors market , as everyone will be waiting to see how much of the excess allocation they’ve won ( and the money they’ve committed is ringfenced by the broker)We are therefore seeing low levels of retail trades, and a stagnant share price